At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCC Warrior Met Coal LLC
Closed 09-22 16:00:00 EDT
92.10
+3.63
+4.10%
盘后92.75
+0.65+0.71%
19:56 EDT
High93.68Low88.49Vol617.11K
Open88.74D1 Closing88.47Amplitude5.87%
Mkt Cap4.84BTradable Cap4.77BTotal Shares52.57M
T/O56.85MT/O Rate1.19%Tradable Shares51.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NYSE Order Imbalance 56938.0 Shares on Sell Side
THOMSON REUTERS  ·  09-17
NYSE Order Imbalance 56938.0 Shares on Sell Side
RBC Raises Price Target on Warrior Met Coal to $110 From $90, Keeps Sector Perform Rating
MT Newswires Live  ·  09-16
RBC Raises Price Target on Warrior Met Coal to $110 From $90, Keeps Sector Perform Rating
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
GlobeNewswire  ·  09-14
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
GlobeNewswire  ·  09-09
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Dow Jones  ·  09-08
Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
GlobeNewswire  ·  09-02
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
GlobeNewswire  ·  09-02
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire  ·  09-01
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Tokio Marine HCC International Acquires UK-Based Direct Commercial
MT Newswires Live  ·  08-31
Tokio Marine HCC International Acquires UK-Based Direct Commercial
Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
Dow Jones  ·  08-28
Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed
Stock News  ·  08-27
IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed
Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million
Reuters  ·  08-26
Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million
Warrior Met Coal Inc : Jefferies Raises Target Price to $125 from $110
THOMSON REUTERS  ·  08-26
Warrior Met Coal Inc : Jefferies Raises Target Price to $125 from $110
Press Release: Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Dow Jones  ·  08-25
Press Release: Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
GlobeNewswire  ·  08-25
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
Press Release: Antengene Announces 2026 Interim Results: Achieves First
Dow Jones  ·  08-24
Press Release: Antengene Announces 2026 Interim Results: Achieves First
Warrior Met Coal Director Stephen D. Williams Sells 4,800 Common Shares Worth $500,304
Reuters  ·  08-22
Warrior Met Coal Director Stephen D. Williams Sells 4,800 Common Shares Worth $500,304
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
GlobeNewswire  ·  08-20
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
GlobeNewswire  ·  08-17
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
Tvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating
TIPRANKS  ·  08-15
Tvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating

Introduction

Company Name.
Warrior Met Coal LLC
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.
Issue price:
--